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Figure 1. Predictive performance of TRM prediction models, adjusted for small size
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HSCT recipients were analyzed. Twenty four variables were
included. In the second phase, by applying a repetitive
computerized simulation, factors necessary for optimal pre-
diction were explored: algorithm type, size of data set,
number of included variables, and performance in speciﬁc
subpopulations. Models were assessed and compared on the
basis of the area under the receiver operating characteristic
curve (AUC).
We developed 6 ML based prediction models for day 100
TRM. Optimal AUCs ranged from 0.65-0.68. Predictive per-
formance plateaued for a population size ranging from
n¼5647-8471, depending on the algorithm (Figure 1). A
feature selection algorithm ranked variables according to
importance. Provided with the ranked variable we data,
discovered that a range of 6-12 ranked variables
were necessary for optimal prediction, depending on the
algorithm. Predictive performance of models developed for
speciﬁc subpopulations ranged from an average of 0.59 to
0.67 for patient in second complete remission and patients
receiving reduced intensity conditioning respectively.
In summary, we present a novel computational approach
for predictionmodel development and analysis in the ﬁeld of
HSCT. Using data commonly collected on transplant patients,
our simulation elucidates outcome prediction limiting fac-
tors. Regardless of the methodology applied, predictive per-
formance converged when sampling more than 5000
patients. Few variables “carry the weight” with regard to
predictive inﬂuence. Overall, the presented ﬁndings reveal a
phenomenon of predictive saturation with data traditionally
collected. Improving predictive performance will likely
require additional types of input like genetic, biologic and
procedural factors.Table 1
Characteristics %
Low risk
(n¼18)
High risk
(n¼18)
Donor Related 17 28
Unrelated 83 72
AL Myeloid 78 67
Lymphoid 22 33
CR# 1st 67 61
2nd 33 39
Conditioning High-dose 50 39
Reduced-intensity 50 61450
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Michigan, Ann Arbor, MIThe HCT-comorbidity index (CI) was developed as a
measure of health-status that could stratify risks of
mortality after HCT. There is a great need for novel
biomarkers that could explain the biologic link but also
increase the objectivity of diagnosing pre-HCT comor-
bidities and increase the predictive power for post-HCT
mortality. MiRs are a class of small non-coding RNAs
(w22 nt) that negatively regulate gene expression.
Studies have uncovered the functional role of miRs in
diverse pathophysiological processes. Moreover, a single
miR could be implicated in different pathological pro-
cesses. To this end, we analyzed miRs as diagnostic for
comorbidities before and as prognostic for mortality
after HCT.
Peripheral blood mononuclear cell samples were pre-
viously collected from 36 pts within 30 days prior to
HCT as a part of research repository. All samples were
collected in EDTA tubes and processed and frozen at -80
Celsius degrees within 8 hours of draw. All pts were in
CR before HCT. Low risk was deﬁned as having HCTCI
score of 0 before and surviving after HCT (median
follow up 56 month, range 12.5-75.5), while high-risk
pts had scores of 4-9 before HCT and none of them
survived HCT (Table 1).
RNA was isolated from PBMC using previously
described methods (Xie LN et al, Clinical Transplant.
2014; 28:314). For discovery of relevant miRs, we used
NanoString nCounter miR assay as previously described
(Knouf EC et al, 2013. PLoS ONE 8: e69630) comprising
654 endogenous miRs. Analysis of miR raw data was
done using nSolverTM 2.0 Software (NanoString Tech-
nologies, Inc.) applying standard quality control tests. All
samples contributed to the discovery analysis. MiRs
Figure 1.
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least 50 counts for the NanoString abundance analyses.
MiR raw data was normalized using the geometric mean
of top 100 miRs (probes with highest 100 counts) as
recommended by the manufacturer. Fold change was
calculated with partitioning by the low- vs high-risk
groups computing two-tailed t-test on the log trans-
formed normalized data that assumes unequal variance.
We used p-value cut-off of <0.1 to identify relevant
miRs. Heat-map analysis used z-score transformation on
samples computing Spearman correlation of the median
between samples.
Among 654 tested miRs, 7 were under-expressed and 12
were over-expressed among the high- vs low-risk group
(Table provided with ﬁgure). Agglomerative cluster “heat-
map” analysis of 16 samples representative of both groups is
shown in Figure.
We identiﬁed a group of MiRs as biomarkers for
pre-transplant relevant comorbidities and increased
post-transplant mortality. Validation of ﬁndings and
determination of gene associations in a larger dataset is
under way.451
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Introduction: Philadelphia chromosome (PH) positive (+)
acute lymphoblastic leukemia (ALL) is incurable without
undergoing allogeneic hematopoietic stem cell transplant
(HCT). Ideally patients should be in complete remission (CR)
prior to HCT without minimal residual disease (MRD). Center
for International Blood and Marrow Research data shows
that ALL patients 20 years of age receiving matched sibling
HCT between 2001-2011, the 3-year survival probabilities
were 53%  1%, 32%  2%, and 23%  2% for patients with
early, intermediate, and advanced disease, respectively.
Corresponding probabilities among the 3,929 recipients of
unrelated donor HCTwere 50% 1%, 34% 2%, and 18% 2%.
Recognizing that patients with PH + ALL have aggressivedisease we questioned if there were factors that would pre-
dict relapse or prevent relapse post HCT in this cohort.
Methods: The HCT database at Mayo Clinic Arizonawas used
to identify patients with Ph + ALL undergoing transplant
from January 1994 through December 2013. 20 PH+ patients
were identiﬁed. Demographic and HCT data were taken from
this database. Data on tyrosine kinase inhibitor (TKI) use and
chimerism were obtained retrospectively from the patient
record.
Results: 6 (30%) patients relapsed and 5 died from their
disease. 1 patient died from transplant related mortality. 5
year survival rate was 59.5%. Of the 6 patients who relapsed
none were MRD positive pre HCT, 3 had 100% donor
chimerism at day 100 and 3 started a TKI post HCT. The 3who
started a TKI did so at day 80, 169 and 172. Conditioning
regimen for these 6 patients consisted of: Fludarabine/
Melphalan/Busulfan (2), Fludarabine/Melphalan (1), Etopo-
side/Cyclophosphamide/Total Body Irradiation (1) and
Cyclophosphamide/Total Body Irradiation (1 ). At HCT 2 pa-
tients were in CR1, 1 in CR2 and 1 in CR3. 1 patient came to
HCT in relapse but did not relapse after. 15 of the 20 patients
were placed on a TKI post HCT. No statistically signiﬁcant
factor was detected to impact relapse or overall survival.
Discussion: PH + ALL is a disease with a poor prognosis. This
study shows a 60% overall survival at 5 years post HCT which
is better than has been reported. We had hypothesized that if
patients were not started on a TKI, had PH + MRD pre or post
HCT, did not reach 100% chimerism at day 100 or did not
receive radiation as part of the conditioning regimen it
would impact relapse. Though this is a small descriptive
study it is notable that there were no trends observed. In the
era where we have many TKIs to choose from perhaps our
outcomes in PH positive ALL are improving. Future research
should focus on conditioning regimen for ALL (full versus
reduced intensity, radiation versus no radiation), optimal
time to start a TKI post HCT and does MRD by PCR pre and
post HCTmatter. Certainly in this study of 20 patients none of
these factors was statistically signiﬁcant. Future study of a
larger population would be prudent.
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